CN108440491A - 含有多个螺碳的螺-环丙基对二烯酮类化合物及其制备方法 - Google Patents

含有多个螺碳的螺-环丙基对二烯酮类化合物及其制备方法 Download PDF

Info

Publication number
CN108440491A
CN108440491A CN201810296610.9A CN201810296610A CN108440491A CN 108440491 A CN108440491 A CN 108440491A CN 201810296610 A CN201810296610 A CN 201810296610A CN 108440491 A CN108440491 A CN 108440491A
Authority
CN
China
Prior art keywords
spiral shell
carbon
cyclopropyl
ketone compounds
containing multiple
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810296610.9A
Other languages
English (en)
Inventor
宋西西
闫丹丹
赵晓露
赵尚昆
朱原原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhengzhou University
Original Assignee
Zhengzhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhengzhou University filed Critical Zhengzhou University
Publication of CN108440491A publication Critical patent/CN108440491A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/613—Unsaturated compounds containing a keto groups being part of a ring polycyclic
    • C07C49/617—Unsaturated compounds containing a keto groups being part of a ring polycyclic a keto group being part of a condensed ring system
    • C07C49/643—Unsaturated compounds containing a keto groups being part of a ring polycyclic a keto group being part of a condensed ring system having three rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/657—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings
    • C07C49/683—Unsaturated compounds containing a keto groups being part of a ring containing six-membered aromatic rings having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/687—Unsaturated compounds containing a keto groups being part of a ring containing halogen
    • C07C49/697—Unsaturated compounds containing a keto groups being part of a ring containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/753—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups
    • C07C49/755—Unsaturated compounds containing a keto groups being part of a ring containing ether groups, groups, groups, or groups a keto group being part of a condensed ring system with two or three rings, at least one ring being a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/16—Quinones the quinoid structure being part of a condensed ring system containing three rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/24—Quinones containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/34—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having three rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/0825—Preparations of compounds not comprising Si-Si or Si-cyano linkages
    • C07F7/083—Syntheses without formation of a Si-C bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/93—Spiro compounds
    • C07C2603/94—Spiro compounds containing "free" spiro atoms

Abstract

本发明公开了一种含有多个螺碳的螺‑环丙基对二烯酮类化合物及其制备方法，该含有多个螺碳的螺‑环丙基对二烯酮类化合物具有多元螺环结构，所述多元螺环结构是通过环丙基三元环上的两个碳分别与两个不同的碳环或杂环以共用螺碳的方式连接而成，其中一个碳环是对二烯酮六元碳环，另一个是含有Linker的环状1,3‑二羰基结构，制备方法如下：在保护气的气氛中，将对亚甲基苯醌类化合物、环状溴代‑1,3‑二羰基化合物、碱溶解在有机溶剂中，在一定温度下搅拌反应，浓缩、柱层析分离，制得含有多个螺碳的多元螺‑环丙基对二烯酮类化合物。该方法在三元环张力比较大且不稳定的情况下，成功的构建了空间结构拥挤的新型多元螺环结构。

Description

含有多个螺碳的螺-环丙基对二烯酮类化合物及其制备方法
技术领域
本发明涉及螺环化合物的合成技术领域，具体涉及含有多个螺碳的新型螺-环丙基对二 烯酮类化合物的合成方法。
背景技术
螺-环丙烷结构广泛存在于自然界天然产物和生物活性分子中，在有机合成和药物化学中 是非常重要的活性中间体。在众多的螺-环丙烷化合物中，螺-环丙基对二烯酮结构具有可以 使DNA发生烷基化反应等重要的分子生物学作用，从而引起了人们的关注研究。目前，合成 螺-环丙基对二烯酮结构的方法主要分为三大类，第一种是通过分子内的烷基化反应生成螺环 化合物[(a)Baird,R.；Winstein,S.J.Am.Chem.Soc.1957,79,4238.(b)Baird,R.；Winstein,S.J. Am.Chem.Soc.1963,85,567.(c)Schwartz,L.H.；Flor,R.V.；Gullo,V.P.J.Org.Chem.1974,39, 219.(d)Schultz,A.G.；Taveras,A.G.TetrahedronLett.1996,37,5853.(e)Arrault,A.；Merour, J.-Y.；Leger,J.-M.；Jarry,C.；Guillaumet,G.Helv.Chim.Acta.2001,84,2198.]。这类合成方法需 要进行多步反应，而且反应条件严苛，需要在强酸强碱环境下进行，副反应多且原子利用率 低，不符合可持续发展的绿色化学理念。第二种是用对醌酮叠氮化合物与烯烃类化合物进行 反应构成螺环化合物[(a)Kende,A.S.；Hebeisen,P.；Sanfilippo,P.J.；Toder,B.H.J.Am.Chem. Soc.1982,104,4244.(b)Becker,H.D.；Elebring,T.J.Org.Chem.1985,50,1319-1322.(c)G.F. Koserand W.H.Pirkle.J.Org.Chem.1967,32,1992.(d)Field,K.W.；Schuster,G.B.J.Org.Chem.1988,53,4000.(e)Nakabayashi,K.；Inoue,S.；Abiko,Y.；Mori,H.Macromolecules.2013, 46,4790.(f)Dao,H.T.；Baran,P.S.Angew.Chem.,Int.Ed.2014,53,14382.]。这类反应以化学稳 定性较差的叠氮醌类为起始底物，反应条件苛刻，且需要较为昂贵的重金属催化剂，这些都 严重限制了其在复杂分子合成及药物化学方面的应用。第三种是用对亚甲基苯醌 (para-Quinone Methides,p-QM)作为受体进行环丙烷化反应[(a)K.Gai,X.Fang,X.Li,J.Xu, X.Wu,A.Lin,H.Yao,Chem.Commun.2015,51,15831.(b)Z.Yuan,X.Fang,X.Li,J.Wu,H. Yao,A.Lin,J.Org.Chem.2015,80,11123；(c)X.-Z.Zhang,J.-Y.Du,Y.-H.Deng,W.-D.Chu,X. Yan,K.-Y.Yu,C.-A.Fan,J.Org.Chem.2016,81,2598.(d)L.Roiser,M.Waser,Org.Lett.2017, 19,2338.]。这些文献中报道的已知合成路线只能构建含有一个螺碳的螺-环丙基对二烯酮的简 单结构，高效地合成结构更加复杂多样的含有多个螺碳的螺-环丙基对二烯酮类化合物的制备 方法还未见文献报道。
发明内容
针对现有技术中存在的问题，本发明提供一种条件温和、原子经济、环境友好且高效快 捷的合成含有多个螺碳的新型螺-环丙基对二烯酮类化合物及其制备方法。
为解决上述技术问题，本发明采用的技术方案：
一种含有多个螺碳的螺-环丙基对二烯酮类化合物，该含有多个螺碳的螺-环丙基对二烯 酮类化合物具有多元螺环结构，所述多元螺环结构是通过环丙基三元环上的两个碳分别与两 个不同的碳环或杂环以共用螺碳的方式连接而成，其中一个碳环是对二烯酮六元碳环，另一 个是含有Linker的环状1,3-二羰基结构，所述螺-环丙基对二烯酮类化合物具有如下通式：
通式A中R1为烷基、硅烷基、烷氧基或芳基，R2为氢、烷基或芳基；通式A中Linker 结构式如下所示：
其中X和Y是相同或者不同的碳(亚甲基、连有一个取代基的次甲基或连有两个取代 基的季碳)、胺(连有一个烷基或芳基取代基的叔胺)或氧，R3和R4是相同或者不同的开链烷基，n是1、2、3或4(分别对应形成螺三元、螺四元、螺五元或螺六元环)。
所述的含有多个螺碳的螺-环丙基对二烯酮类化合物的制备方法，步骤如下：在保护气的 气氛中，将对亚甲基苯醌类化合物、环状溴代-1,3-二羰基化合物、碱溶解在有机溶剂中，在 一定温度下搅拌反应，浓缩、柱层析分离，制得含有多个螺碳的多元螺-环丙基对二烯酮类化 合物。
所述对亚甲基苯醌类化合物具有如下通式：
通式B中R1为烷基、硅烷基、烷氧基或芳基，R2为氢、烷基或芳基。
所述环状溴代-1,3-二羰基化合物具有如下通式：
通式C中的Linker结构式如下所示：
其中X和Y是相同或者不同的碳(亚甲基、连有一个取代基的次甲基或连有两个取代 基的季碳)、胺(连有一个烷基或芳基取代基的叔胺)或氧，R3和R4是相同或者不同的开链烷基，n是1、2、3或4(分别对应形成三元、四元、五元或六元环)。
所述对亚甲基苯醌与环状溴代-1,3-二羰基化合物的摩尔比为1:1-5；所述对亚甲基苯醌与 碱的摩尔比为1:1-5。
所述对亚甲基苯醌与环状溴代-1,3-二羰基化合物的摩尔比为1:3；所述对亚甲基苯醌与碱 的摩尔比为1:2。
所述保护气为氮气或氩气。
所述的碱为碳酸钠(Na2CO3)、碳酸钾(K2CO3)、碳酸氢钠(NaHCO3)、醋酸钠(NaOAc)、氢氧化钾(KOH)、氢氧化钠(NaOH)、碳酸铯(Cs2CO3)、三乙胺(Et3N)、1,8-二氮杂二环 十一碳-7-烯(DBU)、4-二甲氨基吡啶(DMAP)。
所述有机溶剂为二氯甲烷、氯仿、甲苯、四氢呋喃、甲醇、乙醚、二甲基亚砜(DMSO)或N,N-二甲基甲酰胺(DMF)。
所述反应温度为0-30℃，反应时间为0.25-78h。
本发明的有益效果：本发明使用对亚甲基苯醌与环状溴代-1,3-二羰基化合物通过一步直 接串联反应就可以高效合成一系列含有多个螺碳的新型螺-环丙基对二烯酮类化合物。该方法 具有合成步骤简单、反应条件温和、操作简便易行、产物收率高，底物普适性广的特点。该 方法在三元环张力比较大且不稳定的情况下，成功的构建了空间结构拥挤的新型多元螺环结 构。
附图说明
图1为实施例8化合物A1g1a的X射线衍射单晶结构。
具体实施方式
下面结合具体实施例，对本发明做进一步说明。应理解，以下实施例仅用于说明本发明 而非用于限制本发明的范围，该领域的技术熟练人员可以根据上述发明的内容作出一些非本 质的改进和调整。
实施例1
反应条件优化实验：碱的种类、溶剂的种类、温度、物料比等条件进行了筛选。
碱及物料比的优化实验：向20ml反应管中依次加入对亚甲基苯醌化合物(化合物B1a， 29.4mg,0.1mmol)，溴代米氏酸(化合物C1a，44.6mg,0.2mmol)，二氯甲烷(0.5ml)，不同种类的碱(0.2mmol)，在15℃下搅拌反应(反应路线如下所示)，反应结束后，浓缩，柱 色谱分离(石油醚/乙酸乙酯＝20/1，体积比)得到目标产物A1a1a。
不同种类的碱及不同物料比对亚甲基苯醌与溴代米氏酸发生的串联反应获得的结果如 表1中所示。
表1不同种类的碱及不同物料比对串联反应影响的实验结果
反应条件：[a]溴代米氏酸(0.3mmol)；[b]溴代米氏酸(0.25mmol)；[c]溴代米氏酸(0.1 mmol)。
首先以2,6-二叔丁基对亚甲基苯醌化合物B1a与溴代米氏酸C1a为模板反应进行研究 (如表1所示)。一系列不同种类的碱以两倍当量进行筛选(编号1-10)，发现碱的种类对反 应有至关重要的影响，其中有机碱DBU和Et3N的效果最好(编号8-9)，产率在80％左右， 而相比之下无机碱的催化效果不太理想，其中Na2CO3、K2CO3的催化效果相对较好。通过反映研究，发现在反应结束时B1a仍有部分残留，所以接着我们用反应效果较好的不同的碱与三倍当量的C1a反应，继续进行条件优化(编号11-15)。然而无机碱的催化效果并没有随着底物消耗量的增加而有明显变化(编号11-12)，但令人兴奋的是有机碱的催化效果有了明 显的提高(编号13-14)，其中用DBU的催化产率最高达到了96％，而且反应速度有了大幅提高。为了确保筛选结果的准确性，又用DBU与不同当量的C1a进行了对比实验(编号 15-16)，发现C1a的用量对收率有很大的影响，但以编号14中实验效果最佳。
温度及溶剂用量的筛选实验：向20ml反应管中依次加入对亚甲基苯醌化合物(化合物 B1a，29.4mg,0.1mmol)，溴代米氏酸(化合物C1a，66.9mg,0.3mmol)，DBU(0.2mmol)，二氯甲烷(0.5ml)，在不同温度下搅拌反应，反应结束后，浓缩，柱色谱分离(石油醚/乙酸乙酯＝20/1，体积比)得到目标产物A1a1a。不同的温度及溶剂的量对亚甲基苯醌与溴代米氏酸发生串联反应获得的结果如表2中所示。
表2不同的温度及溶剂的量对串联反应影响的实验结果
[a]二氯甲烷(1.0ml)。
探究温度对反应的影响以及确定反应的最宜温度，对温度进行了筛选(如表2所示)。 随着温度的升高反应副产物增多，而且反应底物B1a质量增加，此条件下产率为85％；当反 应温度在0℃时除了反应速度降低外，产率受到轻微影响(编号1)，与在15℃时反应产率几 乎一样。同时我们对溶剂的用量也进行了一组对比实验(编号4)，反应产率也有所下降。
溶剂种类的筛选实验：向20ml反应管中依次加入对亚甲基苯醌化合物(化合物B1a， 29.4mg,0.1mmol)，溴代米氏酸(化合物C1a，44.6mg,0.2mmol)，DBU(0.2mmol)，在 15℃下不同种类有机溶剂中搅拌反应，反应结束后，浓缩，柱色谱分离(石油醚/乙酸乙酯＝20/1，体积比)得到目标产物A1a1a。不同种类溶剂对亚甲基苯醌与溴代米氏酸发生串联反应 获得的结果如表3中所示。
表3不同种类溶剂对串联反应影响的实验结果
[a]不反应(No Reaction)。
通过2,6-二叔丁基对亚甲基苯醌B1a与溴代米氏酸C1a的反应条件的筛选， 得到最优的反应条件如下：反应温度为15℃，2,6-二叔丁基对亚甲基苯醌与溴代 米氏酸的物料比为1:3，碱为DBU，2,6-二叔丁基对亚甲基苯醌与DBU的物料比 为1:2，二氯甲烷作为溶剂。
实施例2
含有多个螺碳的新型螺-环丙基对二烯酮类化合物的制备。
按照实施例1中得到的最佳反应条件作为通用反应条件，使用带有不同取代基团的对亚 甲基苯醌B和各种环状溴代-1,3-二羰基化合物C作为反应原料(反应路线如下所示)，成功 的合成得到一系列新型螺-环丙基对二烯酮类化合物(表4)。
表4含有多个螺碳的新型螺-环丙基对二烯酮类化合物的制备结果
本实施例以化合物A1a1a的制备为例详细说明本发明所述的具有多个螺碳的螺环丙基- 对二烯酮类化合物的制备方法：向20ml反应管中依次加入对亚甲基苯醌化合物(化合物B1a， 29.4mg,0.1mmol)，环状溴代-1,3-二羰基化合物(化合物C1a，66.9mg,0.3mmol)，DBU (0.2mmol)，二氯甲烷(0.5ml)，在15℃下搅拌反应，反应结束后，浓缩，柱色谱分离(石油醚/乙酸乙酯＝20/1，体积比)得到目标产物螺环丙基-对二烯酮类化合物A1a1a。
化合物A1a1a的结构式和实验数据：
(A1a1a):浅黄色固体，96％产率；熔点为85-87℃.1H NMR(400MHz,CDCl3)δ＝7.36-7.35(m,3H),7.17-7.16(m,2H),6.69(d,J＝2.3Hz,1H),6.60(d,J＝2.3Hz,1H),4.63(s, 1H),1.74(s,3H),1.33(s,3H),1.26(s,9H),1.19(s,9H)ppm.13C NMR(101MHz,CDCl3)δ＝ 184.63,164.51,161.84,153.82,153.32,134.50,131.78,130.61,129.33,127.98,104.90,77.32, 77.00,76.68,46.24,43.85,42.27,35.98,35.73,29.24,29.21,27.54,26.88ppm.HRMS(ESI):m/z 理论计算值[C27H32O5+Na]+:459.2142；检测得到459.2143.
实施例3
(A1b1a):浅黄色固体，89％产率；熔点为86-88℃.1H NMR(400MHz,CDCl3)δ＝7.07(d,J＝8.3Hz,2H),6.88(d,J＝8.7Hz,2H),6.70(d,J＝2.8Hz,1H),6.59(d,J＝2.8Hz,1H),4.58 (s,1H),3.82(s,3H),1.74(s,3H),1.32(s,3H),1.26(s,9H),1.19(s,9H)ppm.13C NMR(101MHz, CDCl3)δ＝184.71,164.63,161.96,159.15,153.76,153.30,134.69,131.95,130.49,128.73,122.49, 114.09,113.74,104.89,55.23,46.49,43.52,42.32,36.02,35.76,29.29,29.23,27.59,26.90ppm. HRMS(ESI):m/z理论计算值[C28H34O6+Na]+:489.2248；检测得到489.2247.
实施例4
(A1c1a):浅黄色固体，89％产率；熔点为106-108℃.1H NMR(400MHz,CDCl3)δ＝7.35(m, 1H),7.04(d,J＝8.5Hz,1H),6.96-6.89(m,2H),6.76(d,J＝2.8Hz,1H),6.66(d,J＝2.8Hz,1H) 4.31(s,1H),3.78(s,3H),1.74(s,3H),1.33(s,3H),1.26(s,9H),1.19(s,9H)ppm.13C NMR(101 MHz,CDCl3)δ＝184.86,164.73,162.18,158.17,153.43,152.75,134.98,132.38,129.50,129.30, 120.11,119.72,110.30,104.50,55.57,45.89,42.63,40.62,35.94,35.72,29.31,27.58,26.92,26.83 ppm.HRMS(ESI):m/z理论计算值[C28H34O6+Na]+:489.2248；检测得到489.2249.
实施例5
(A1d1a):浅黄色固体，88％产率；熔点为87-89℃.1H NMR(400MHz,CDCl3)δ＝7.16(d,J＝7.9Hz,2H),7.04(d,J＝7.8Hz,2H),6.69(d,J＝2.8Hz,1H),6.59(d,J＝2.8Hz,1H),4.59 (s,1H),2.37(s,3H),1.74(s,3H),1.32(s,3H),1.26(s,9H),1.19(s,9H)ppm.13C NMR(101MHz, CDCl3)δ＝184.73,164.63,161.91,153.79,153.26,137.74,134.66,131.98,129.20,129.08, 127.55,104.89,46.42,45.89,43.81,42.34,36.02,35.77,29.30,29.28,27.60,26.92,21.29ppm. HRMS(ESI):m/z理论计算值[C28H34O5+Na]+:473.2298；检测得到473.2297.
实施例6
(A1e1a):浅黄色固体，90％产率；熔点为93-95℃.1H NMR(400MHz,CDCl3)δ＝7.28(m,1H),7.20(m,2H),7.05(d,J＝7.6Hz,1H),6.79(d,J＝2.8Hz,1H),6.60(s,J＝2.8Hz,1H),4.40(s,1H),2.19(s,3H),1.74(s,3H),1.33(s,3H),1.27(s,9H),1.21(s,9H)ppm.13CNMR (101MHz,CDCl3)δ＝184.62,164.44,162.01,153.96,153.03,137.83,134.72,132.20,130.32, 129.65,128.68,128.27,125.66,104.93,46.18,43.26,42.62,36.04,35.78,29.30,29.27,27.58, 26.84,19.73ppm.HRMS(ESI):m/z理论计算值[C28H34O5+Na]+:473.2298；检测得到 473.2296.
实施例7
(A1f1a):浅黄色固体，96％产率；熔点为89-91℃.1H NMR(400MHz,CDCl3)δ＝7.23(d,J＝8.0Hz,1H),7.14(d,J＝7.6Hz,1H),6.96(d,J＝7.4Hz,2H),6.71(d,J＝2.8Hz,1H),6.59 (s,J＝2.8Hz,1H),4.60(s,1H),2.34(s,3H),1.74(s,3H),1.33(s,1H),1.26(s,9H),1.19(s,9H) ppm.13C NMR(101MHz,CDCl3)δ＝184.73,164.61,161.87,153.80,153.16,137.97,134.59, 132.03,130.55,130.10,128.80,128.21,126.40,104.92,46.28,43.92,42.34,36.03,35.78,29.30, 29.29,27.60,26.91,21.41ppm.HRMS(ESI):m/z理论计算值[C28H34O5+Na]+:473.2298；检测 得到473.2299.
实施例8
(A1g1a):浅黄色固体，98％产率；熔点为98-101℃.1H NMR(400MHz,CDCl3)δ＝7.48(d,J＝8.4Hz,2H),7.04(d,J＝7.8Hz,2H),6.60(d,J＝2.9Hz,1H),6.56(d,J＝2.9Hz,1H),4.52 (s,1H),1.74(s,3H),1.32(s,3H),1.25(s,9H),1.18(s,9H)ppm.13C NMR(101MHz,CDCl3)δ＝ 184.53,164.31,161.88,154.12,153.86,134.18,131.52,131.20,131.08,129.75,122.15,105.09, 46.07,45.89,43.02,42.17,36.08,35.81,29.27,27.58,26.95,ppm.HRMS(ESI):m/z理论计算值 [C27H31BrO5+Na]+:537.1247；检测得到537.1248.
实施例9
(A1h1a):浅黄色固体，88％产率；熔点为102-104℃.1H NMR(400MHz,CDCl3)δ＝7.44(d,J＝7.8Hz,2H),7.29(m,2H),7.16(d,J＝7.4Hz,1H),6.74(s,1H),6.65(s,1H),4.40(s, 1H),1.75(s,3H),1.34(d,J＝0.8Hz 3H),1.26(d,J＝1.8Hz 9H),1.20(d,J＝1.8Hz9H)ppm.13C NMR(101MHz,CDCl3)δ＝184.60,164.18,162.05,153.91,153.30,135.57,134.39,131.44, 130.05,129.55,126.54,104.89,45.94 42.78,42.62,36.05,35.80,29.28,28.82,27.51,26.96,ppm. HRMS(ESI):m/z理论计算值[C27H31ClO5+Na]+:493.1752；检测得到493.1753.
实施例10
(A1i1a):浅黄色固体，94％产率；熔点为86-89℃.1H NMR(400MHz,CDCl3)δ＝7.33(d,J＝8.4Hz,2H),7.10(d,J＝8.4Hz,2H),6.61(d,J＝2.9Hz,1H),6.57(d,J＝2.8Hz,1H),4.55 (s,1H),1.75(s,3H),1.32(s,3H),1.26(s,9H),1.18(s,9H)ppm.13C NMR(101MHz,CDCl3)δ＝ 184.54,164.32,161.88,154.12,153.84,134.20,133.98,131.23,130.75,129.22,128.58,105.08, 46.13,42.98,42.22,36.07,35.80,29.27,28.58,26.94,ppm.HRMS(ESI):m/z理论计算值 [C27H31ClO5+Na]+:493.1752；检测得到493.1753.
实施例11
(A1j1a):浅黄色固体，90％产率；熔点为94-96℃.1H NMR(400MHz,CDCl3)δ＝7.32-7.27(m,2H),7.16(s,1H),7.08-7.06(m,1H),6.63(d,J＝2.8Hz,1H),6.56(s,J＝2.8Hz, 1H),4.56(s,1H),1.75(s,3H),1.33(s,3H),1.26(s,9H),1.20(s,9H)ppm.13C NMR(101MHz, CDCl3)δ＝184.53,164.26,161.81,154.14,153.81,134.18,134.07,132.66,131.17,129.59, 129.55,128.28,127.69,105.13,45.90 42.88,42.16,36.10,35.82,29.28,29.26,27.57,26.93,ppm. HRMS(ESI):m/z理论计算值[C27H31ClO5+Na]+:493.1752；检测得到493.1754.
实施例12
(A1k1a):浅黄色固体，70％产率；熔点为105-107℃.1H NMR(400MHz,CDCl3)δ＝7.62(d,J＝8.0Hz,2H),7.30-7.27(m,2H),6.59(s,2H),4.60(s,1H),1.76(s,3H),1.33(s,3H), 1.27(s,9H),1.19(s,9H)ppm.13C NMR(101MHz,CDCl3)δ＝184.46,164.22,161.91,154.28, 154.10,134.81,134.01,130.91,129.83,125.34,125.30,105.23,45.97,42.96,42.19,36.12,35.85, 29.27,28.63,27.57,26.98,26.92,ppm.HRMS(ESI):m/z理论计算值[C28H31F3O5+Na]+: 527.2016；检测得到527.2015.
实施例13
(A1l1a):浅黄色固体，92％产率；熔点为89-93℃.1H NMR(400MHz,CDCl3)δ＝7.15-7.12(m,2H),7.07-7.03(m,2H),6.62(d,J＝2.9Hz,1H),6.58(d,J＝2.8Hz,1H),4.57(s, 1H),1.75(s,3H),1.33(s,3H),1.26(s,9H),1.18(s,9H)ppm.13C NMR(101MHz,CDCl3)δ＝ 184.58,164.40,161.94,154.03,153.72,134.33,131.39,131.11,131.03,126.41,125.37,115.52, 115.30,105.05,46.25,43.01,42.22,36.07,35.80,29.28,29.26,27.59,26.98,26.94,ppm. HRMS(ESI):m/z理论计算值[C27H31FO5+Na]+:477.2048；检测得到477.2047.
实施例14
(A1m1a):浅黄色固体，92％产率；熔点为108-110.1H NMR(400MHz,CDCl3)δ＝7.91-7.86(m,2H),7.68-7.65(m,1H),7.53-7.49(m,2H),7.46-7.42(m,1H),7.30(d,J＝7.2Hz, 1H),6.83(d,J＝2.8Hz,1H),6.72(d,J＝2.9Hz,1H),4.81(s,1H),1.75(s,3H),1.36(s,3H),1.30 (s,9H),1.19(s,9H)ppm.13C NMR(101MHz,CDCl3)δ＝186.06,166.10 162.98,155.59,154.58, 136.07,134.90,133.86,133.76,130.47,130.43,128.75,128.33,128.31,127.46,126.18,124.33, 105.46,47.36,44.45,43.73,37.43,37.25,30.74,30.62,28.97,28.30ppm.HRMS(ESI):m/z理论 计算值[C31H34O5+Na]+:509.2298；检测得到509.2297.
实施例15
(A1n1a):浅黄色固体，94％产率；熔点为86-88℃.1H NMR(400MHz,CDCl3)δ＝7.87-7.83(m,2H),7.77-7.75(m,1H),7.61(s,1H),7.51-7.48(m,2H),7.30-7.27(dd,J＝8.6,1.4Hz, 1H),6.78(d,J＝2.8Hz,1H),6.65(d,J＝2.8Hz,1H),4.76(s,1H),1.76(s,3H),1.35(s,3H),1.29 (s,9H),1.19(s,9H)ppm.13C NMR(101MHz,CDCl3)δ＝184.75,164.58,161.94,153.99, 153.46,134.49,133.09,132.87,131.89,128.33,128.27,128.07,127.87,127.66,127.23,126.48, 126.37,105.01,46.38,43.99,42.35,36.08,35.86,29.33,27.62,26.93ppm.HRMS(ESI):m/z理论 计算值[C31H34O5+Na]+:509.2298；检测得到509.2299.
实施例16
(A1o1a):浅黄色固体，80％产率；熔点为103-105℃.1H NMR(400MHz,CDCl3)δ＝7.23-7.21(m,1H),7.00(d,J＝7.4Hz,1H),6.94-6.90(m,1H),6.85(d,J＝8.2Hz,2H),6.74(d,J＝ 2.8Hz,1H),6.66(d,J＝2.8Hz,1H),4.35(s,1H),1.70(s,3H),1.31(s,3H),1.26(s,9H),1.19(s, 9H),0.95(s,9H)ppm.13C NMR(101MHz,CDCl3)δ＝184.84,164.71,161.91,154.87,153.47, 152.64,135.12,132.65,130.13,12921,121.70,120.36,118.05,104.54,45.56,42.65,41.24,35.95, 35.74,30.29,29.32,29.29,27.58,26.99,26.92,25.93,18.40ppm.HRMS(ESI):m/z理论计算值 [C29H34O5+Na]+:589.2956；检测得到589.2958.
实施例17
(A1p1a):浅黄色固体，94％产率；熔点为77-79℃.1H NMR(400MHz,CDCl3)δ＝7.32(d,J＝5.0Hz,1H),7.02-7.00(m,1H),6.96-6.95(m,2H),6.56(d,J＝2.8Hz,1H),4.60(s,1H), 1.74(s,3H),1.33(s,3H),1.25(s,9H),1.23(s,9H)ppm.13C NMR(101MHz,CDCl3)δ＝184.58, 164.05,161.55,153.98,153.73,133.91,132.64,131.06,128.54,126.67,126.19,104.98,46.28, 42.85,39.00,36.08,35.79,29.25,27.58,26.93ppm.HRMS(ESI):m/z理论计算值 [C25H30O5S+Na]+:465.1706；检测得到465.1705.
实施例18
(A1q1a):浅黄色固体，93％产率；熔点为86-89℃.1H NMR(400MHz,CDCl3)δ＝7.44(t,J＝1.8Hz,1H),6.96(d,J＝2.9Hz,1H),6.54(d,J＝2.9Hz,1H),6.41(m,1H),6.29(m,1H), 4.38(s,1H),1.73(s,3H),1.33(s,3H),1.24(s,9H),1.23(s,9H)ppm.13C NMR(101MHz,CDCl3) δ＝184.57,163.88,161.56,154.09,153.66,144.70,142.79,133.69,131.20,110.70,110.22,105.00, 45.07,41.93,36.61,35.79,29.28,29.24,27.57,26.92ppm.HRMS(ESI):m/z理论计算值 [C25H30O6+Na]+:449.1935；检测得到449.1936.
实施例19
(A1a1b):白色固体，94％产率；熔点为145-147℃.1H NMR(400MHz,CDCl3)δ＝7.26-7.18(m,3H),6.92-6.90(m,2H),6.63-6.62(d,J＝3.1Hz,2H),2.60-2.46(m,2H),2.41-2.32 (m,2H),1.30(s,3H),1.27(s,9H),1.21(s,3H),0.85(s,9H)ppm.13C NMR(101MHz,CDCl3)δ ＝193.76,185.53,175.78,146.91,146.64,137.56,136.86,136.64,128.60,127.75,127.64,113.90, 88.26,55.30,51.34,38.30,34.81,34.56,34.21,30.24,29.37,28.98,28.89,28.80,26.92,ppm. HRMS(ESI):m/z理论计算值[C29H36O3+Na]+:455.2557；检测得到455.2558.
实施例20
(A1a1c):白色固体，77％产率；熔点为141-145℃.1H NMR(400MHz,CDCl3)δ＝7.24-7.20(m,3H),6.92-6.90(m,2H),6.63(d,J＝3.1Hz,1H),5.91(d,J＝3.1Hz,1H),4.40(s, 1H),2.72-2.62(m,2H),2.52-2.45(m,2H),2.25-2.21(m,2H),1.27(s,9H),0.85(s,9H)ppm.13C NMR(101MHz,CDCl3)δ＝193.76,185.53,175.78,146.91,146.64,137.56,136.86,136.64, 128.60,127.75,127.64,113.90,88.26,55.30,51.34,38.30,34.81,34.56,34.21,30.24,29.37,28.98, 28.89,28.80,26.92,ppm.HRMS(ESI):m/z理论计算值[C27H32O2+Na]+:427.2244；检测得到 427.2245.
实施例21
(A1a2a):浅黄色固体，96％产率；熔点为110-113℃.1H NMR(400MHz,CDCl3)δ＝7.34(d,J＝7.3Hz,3H),7.17-7.15(m,2H),6.66(d,J＝2.9Hz,1H),6.57(d,J＝2.8Hz,1H),4.62 (s,1H),1.98-1.92(m,2H),1.75-1.74(d,J＝5.5Hz,2H),1.43(s,6H),1.26(s,9H),1.18(s,9H) ppm.13C NMR(101MHz,CDCl3)δ＝184.78,164.61,161.89,153.91,153.36,134.66,131.95, 130.78,129.40,128.27,127.95,105.78,46.21,43.82,42.69,36.49,35.95,35.85,35.69,29.29, 29.26,23.93,22.64,21.61,ppm.HRMS(ESI):m/z理论计算值[C29H34O5+Na]+:499.2455；检测 得到499.2454.
实施例22
(A1a2b):浅黄色固体，93％产率；熔点为81-84℃.1H NMR(400MHz,CDCl3)δ＝7.36-7.34(m,3H),7.17-7.15(m,2H),6.63(d,J＝2.9Hz,1H),6.54(d,J＝2.9Hz,1H),4.60(s, 1H),2.22-2.19(m,2H),1.81-1.70(m,4H),1.57-1.56(m,2H),1.27(s,9H),1.19(s,9H)ppm.13C NMR(101MHz,CDCl3)δ＝184.73,165.11,162.42,153.83,153.30,134.70,131.93,130.59, 129.45,128.28,128.00,114.12,46.22,43.64,42.63,38.76,37.94,35.98,35.73,29.28,29.26,23.88, 22.35ppm.HRMS(ESI):m/z理论计算值[C30H36O5+Na]+:485.2298；检测得到485.2297.
实施例23
(A1r1a):浅黄色固体，83％产率；熔点为106-109℃.1H NMR(400MHz,CDCl3)δ＝8.24(d,J＝8.7Hz,2H),7.36(d,J＝8.1Hz,2H),6.58(d,J＝2.9Hz,1H),6.53(d,J＝2.8Hz,1H), 4.61(s,1H),1.77(s,3H),1.34(s,3H),1.27(s,9H),1.19(s,9H)ppm.13C NMR(101MHz,CDCl3) δ＝184.31,163.97,161.96,154.54,154.51,138.23,133.63,130.48,130.35,128.66,123.81,123.58, 105.43,45.82,42.55,42.25,36.18,35.89,29.26,28.77,27.55,27.00,ppm.HRMS(ESI):m/z理论 计算值[C27H31NO7+Na]+:504.1993；检测得到504.1992.
实施例24
(A1g1b):白色固体，93％产率；熔点为68-70℃.1H NMR(400MHz,CDCl3)δ＝ 7.39-7.37(d,J＝8.4Hz,2H),6.78(d,J＝8.4Hz,2H),6.61(d,J＝3.1Hz,1H),5.93(d,J＝3.1Hz,2H),4.35(s,1H),2.59-2.45(m,2H),2.41-2.31(m,2H),1.28(s,3H),1.26(s,9H),1.21(s,3H), 0.89(s,9H)ppm.13C NMR(101MHz,CDCl3)δ＝193.67,185.43,176.11,147.35,146.97,137.31,136.08,135.95,131.68,129.39,121.56,113.47,88.13,54.82,51.29,38.28,34.85,34.66, 34.25,29.36,28.92,28.86,28.83,26.92ppm.HRMS(ESI):m/z理论计算值[C29H35BrO3+Na]+: 533.1662；检测得到533.1663.
实施例25
(A1b1b):白色固体，85％产率；熔点为138-140℃.1H NMR(400MHz,CDCl3)δ＝6.84-6.82(m,2H),6.79-6.77(m,2H),6.61(d,J＝3.1Hz,1H),5.96(d,J＝3.1Hz,1H),4.35(s,1H), 3.74(s,3H),2.59-2.45(m,2H),2.40-2.31(m,2H),1.29(s,3H),1.26(s,9H),1.21(s,3H),0.88(s, 9H)ppm.13C NMR(101MHz,CDCl3)δ＝193.83,185.61,175.64,159.12,146.87,146.58, 137.62,136.80,129.02,128.72,114.08,88.36,55.35,54.63,51.35,38.30,34.79,34.59,34.19, 29.37,28.96,28.87,26.91ppm.HRMS(ESI):m/z理论计算值[C30H38O4+Na]+:485.2662；检测 得到485.2663.
实施例26
(A1s1a):白色固体，70％产率；熔点为106-109℃.1H NMR(400MHz,CDCl3)δ＝6.50(s,2H),2.84(s,2H),1.75(s,3H),1.32(s,3H),1.22(s,18H)ppm.13C NMR(101MHz,CDCl3)δ＝184.53,164.11,154.00,133.72,105.26,43.91,39.53,35.73,34.59,29.22,27.64,26.86,26.65 ppm.IR():HRMS(ESI):m/z理论计算值[C21H28O4+H]+:361.2010；检测得到361.2011.
实施例27
(A2a1a):白色固体，79％产率；熔点为106-109℃.1H NMR(400MHz,CDCl3)δ＝7.28-7.26(m,3H),7.19-7.16(m,2H),6.92(d,J＝1.3Hz,1H),6.64(d,J＝1.3Hz,1H),4.35(s,1H), 2.36(s,6H),1.65(s,3H),1.46(s,3H)ppm.13C NMR(101MHz,CDCl3)δ＝186.15,170.42, 158.64,153.82,136.87,131.78,129.62,104.89,46.63,36.04,29.30,27.49,16.89,16.76ppm. HRMS(ESI):m/z理论计算值[C21H20O5+Na]+:375.1203；检测得到37501204.
实施例28
(A3a1a):白色固体，82％产率；熔点为97-99℃.1H NMR(400MHz,CDCl3)δ＝ 7.31-7.29(m,3H),7.21-7.18(m,2H),6.86(d,J＝3.1Hz,1H),6.59(d,J＝3.1Hz,1H),4.31(s,1H), 3.26(m,2H),1.64(s,3H),1.45(s,3H),1.16-1.09(m,12H)ppm.13C NMR(101MHz,CDCl3)δ ＝187.61,169.32,153.23,149.89,144.65,130.18,127.69,104.70,46.73,36.74,32.20,27.21,27.20, 21.42,21.40ppm.HRMS(ESI):m/z理论计算值[C25H28O5+Na]+:431.1829；检测得到 431.1828.
实施例29
(A4a1a):白色固体，82％产率；熔点为78-80℃.1H NMR(400MHz,CDCl3)δ＝ 7.58-7.49(m,9H),7.40-7.28(m,6H),6.88(s,1H),6.84(s,1H),4.36(s,1H),1.65(s,3H),1.49(s, 3H)ppm.13C NMR(101MHz,CDCl3)δ＝187.38,170.22,146.21,144.66,142.46,132.68,128.96,128.85,127.42,104.98,46.76,36.78,30.21,27.22,27.20ppm.HRMS(ESI):m/z理论计 算值[C31H24O5+Na]+:499.1516；检测得到49.
实施例30
(A5a1a):白色固体，89％产率；熔点为125-127℃.1H NMR(400MHz,CDCl3)δ＝7.28-7.24(m,3H),7.19-7.10(m,2H),6.96(d,J＝3.1Hz,1H),6.59(d,J＝3.1Hz,1H),4.32(s,1H), 1.66(s,3H),1.49(s,3H),0.08(m,18H)ppm.13C NMR(101MHz,CDCl3)δ＝189.78,168.12, 165.02,148.96,145.25,130.18,127.69,104.69,46.70,36.64,27.22,27.19,3.5ppm.HRMS(ESI): m/z理论计算值[C25H32O5Si2+Na]+:491.1680；检测得到491.1677.
实施例31
(A6a1a):白色固体，76％产率；熔点为135-137℃.1H NMR(400MHz,CDCl3)δ＝7.26-7.22(m,3H),7.19-7.10(m,2H),6.86(d,J＝3.1Hz,1H),6.64(d,J＝3.1Hz,1H),4.30(s,1H), 4.09(s,3H),3.89(s,3H)1.66(s,3H),1.49(s,3H)ppm.13C NMR(101MHz,CDCl3)δ＝182.65, 168.22,152.12,144.82,145.34,129.65,127.47,124.61,104.70,56.12,46.71,36.68,27.22,27.19, 23.57ppm.HRMS(ESI):m/z理论计算值[C21H20O7+Na]+:407.1101；检测得到40701103.
实施例32
(A1a3a):浅黄色固体，78％产率；熔点为86-89℃.1H NMR(400MHz,CDCl3)δ＝7.31-7.28(m,3H),7.19-7.16(m,2H),6.67(d,J＝2.3Hz,1H),6.58(d,J＝2.3Hz,1H),4.61(s, 1H),3.25(s,3H),3.22(s,3H),1.70(s,3H),1.36(s,3H),1.25(s,9H),1.18(s,9H)ppm.13C NMR (101MHz,CDCl3)δ＝185.63,174.51,152.84,150.82,145.32,130.61,129.33,126.98,44.24, 41.85,37.27,35.98,29.24,29.21ppm.HRMS(ESI):m/z理论计算值[C27H32N2O4+Na]+: 471.2254；检测得到471.2253.
实施例33
(A1a4a):浅黄色固体，72％产率；熔点为97-98℃.1H NMR(400MHz,CDCl3)δ＝7.84-7.80(m,2H),7.43-7.32(m,2H),δ＝7.31-7.28(m,3H),7.19-7.16(m,2H),6.65(d,J＝2.3Hz, 1H),6.59(d,J＝2.3Hz,1H),4.43(s,1H),1.25(s,9H),1.18(s,9H)ppm.13C NMR(101MHz, CDCl3)δ＝200.07,189.51,184.56,152.96,150.89,144.32,134.61,129.43,125.98,120.556, 118.16,52.24,35.85,29.24,29.21ppm.HRMS(ESI):m/z理论计算值[C30H30O4+Na]+: 477.2036；检测得到477.2038.
实施例34
(A1a5a):浅黄色固体，81％产率；熔点为86-89℃.1H NMR(400MHz,CDCl3)δ＝8.31-8.35(m,4H),7.74(m,2H),δ＝7.30-7.28(m,3H),7.18-7.16(m,2H),6.67(d,J＝2.3Hz,1H), 6.60(d,J＝2.3Hz,1H),4.41(s,1H),1.24(s,9H),1.19(s,9H)ppm.13C NMR(101MHz,CDCl3) δ＝200.06,189.57,152.76,144.32,143.56 134.61,133.12 129.44,125.98,126.56,125.13,58.24, 36.85,35.18,29.24,29.21,28.65ppm.HRMS(ESI):m/z理论计算值[C34H32O3+Na]+:511.2244； 检测得到511.2246.
实施例35
(A1a6a):白色固体，77％产率；熔点为141-145℃.1H NMR(400MHz,CDCl3)δ＝7.28-7.25(m,3H),7.19-7.17(m,2H),6.46(d,J＝3.1Hz,1H),6.12(d,J＝3.1Hz,1H),4.40(s, 1H),2.78-2.68(m,2H),2.52-2.45(m,2H),2.25-2.21(m,2H),1.27(s,9H),0.95(s,9H)ppm.13C NMR(101MHz,CDCl3)δ＝210.31,189.53,175.78,146.91,146.64,137.56,136.86,136.64, 128.60,127.75,127.64,113.90,88.26,55.30,51.34,38.30,34.81,34.21,30.24,29.37,28.98,28.89, 28.80,ppm.HRMS(ESI):m/z理论计算值[C26H30O3+Na]+:413.2087；检测得到413.2085.
实施例36
(A1t1a):白色固体，65％产率；熔点为101-103℃.1H NMR(400MHz,CDCl3)δ＝6.47(d, J＝3.1Hz,2H),3.45(m,1H),1.75(s,3H),1.71(s,3H),1.22(s,18H),0.93(d,J＝1.3Hz,3H)ppm. 13C NMR(101MHz,CDCl3)δ＝186.53,168.11,149.05,147.72,104.89,47.22,35.73,31.59, 29.89,27.64,24.86,16.65ppm.HRMS(ESI):m/z理论计算值[C22H30O5+Na]+:397.1985；检测 得到397.1982.
实施例37
(A1u1a):白色固体，68％产率；熔点为121-123℃.1H NMR(400MHz,CDCl3)δ＝6.45(d,J＝3.1Hz,2H),3.46(s,1H),1.74(s,3H),1.71(s,3H),1.22(s,18H),0.95(s,9H)ppm.13C NMR(101MHz,CDCl3)δ＝186.59,168.21,149.25,146.72,104.88,47.29,39.73,35.59,30.89, 27.64,27.46,24.56ppm.HRMS(ESI):m/z理论计算值[C25H36O5+Na]+:439.2455；检测得到 439.2453.
以上显示和描述了本发明的基本原理和主要特征以及本发明的优点。本行业的技术人员 应该了解，本发明不受上述实施例的限制，上述实施例和说明书中描述的只是说明本发明的 原理，在不脱离本发明精神和范围的前提下，本发明还会有各种变化和改进，这些变化和改 进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界 定。

Claims (10)

1.一种含有多个螺碳的螺-环丙基对二烯酮类化合物，其特征在于：该含有多个螺碳的螺-环丙基对二烯酮类化合物具有多元螺环结构，所述多元螺环结构是通过环丙基三元环上的两个碳分别与两个不同的碳环或杂环以共用螺碳的方式连接而成，其中一个碳环是对二烯酮六元碳环，另一个是含有Linker的环状1,3-二羰基结构，所述螺-环丙基对二烯酮类化合物具有如下通式：
通式A中R1为烷基、硅烷基、烷氧基或芳基，R2为氢、烷基或芳基；通式A中Linker结构式如下所示：
其中X和Y是相同或者不同的碳、胺或氧，R3和R4是相同或者不同的开链烷基，n是1、2、3或4。
2.根据权利要求1所述的含有多个螺碳的螺-环丙基对二烯酮类化合物的制备方法，其特征在于制备步骤如下：在保护气的气氛中，将对亚甲基苯醌类化合物、环状溴代-1,3-二羰基化合物、碱溶解在有机溶剂中，在一定温度下搅拌反应，浓缩、柱层析分离，制得含有多个螺碳的螺-环丙基对二烯酮类化合物。
3.根据权利要求2所述的含有多个螺碳的新型螺-环丙基对二烯酮类化合物的制备方法，其特征在于：所述对亚甲基苯醌类化合物具有如下通式：
通式B中R1为烷基、硅烷基、烷氧基或芳基，R2为氢、烷基或芳基。
4.根据权利要求2所述的含有多个螺碳的新型螺-环丙基对二烯酮类化合物的制备方法，其特征在于：所述环状溴代-1,3-二羰基化合物具有如下通式：
通式C中的Linker为不同的连接结构，结构式如下所示：
其中X和Y是相同或者不同的碳、胺或氧，R3和R4是相同或者不同的开链烷基，n是1、2、3或4。
5.根据权利要求2所述的含有多个螺碳的螺-环丙基对二烯酮类化合物的制备方法，其特征在于：所述对亚甲基苯醌与环状溴代-1,3-二羰基化合物的摩尔比为1:1-5；所述对亚甲基苯醌与碱的摩尔比为1:1-5。
6.根据权利要求5所述的含有多个螺碳的螺-环丙基对二烯酮类化合物的制备方法，其特征在于：所述对亚甲基苯醌与环状溴代-1,3-二羰基化合物的摩尔比为1:3；所述对亚甲基苯醌与碱的摩尔比为1:2。
7.根据权利要求2所述的含有多个螺碳的螺-环丙基对二烯酮类化合物的制备方法，其特征在于：所述保护气为氮气或氩气。
8.根据权利要求2所述的含有多个螺碳的螺-环丙基对二烯酮类化合物的制备方法，其特征在于：所述的碱为碳酸钠、碳酸钾、碳酸氢钠、醋酸钠、氢氧化钾、氢氧化钠、碳酸铯、三乙胺、1,8-二氮杂二环十一碳-7-烯、4-二甲氨基吡啶。
9.根据权利要求2所述的含有多个螺碳的螺-环丙基对二烯酮类化合物的制备方法，其特征在于：所述有机溶剂为二氯甲烷、氯仿、甲苯、四氢呋喃、甲醇、乙醚、二甲基亚砜或N,N-二甲基甲酰胺。
10.根据权利要求2所述的含有多个螺碳的螺-环丙基对二烯酮类化合物的制备方法，其特征在于：所述反应温度为0-30℃，反应时间为0.25-78h。
CN201810296610.9A 2018-03-30 2018-04-03 含有多个螺碳的螺-环丙基对二烯酮类化合物及其制备方法 Pending CN108440491A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810275923 2018-03-30
CN2018102759236 2018-03-30

Publications (1)

Publication Number Publication Date
CN108440491A true CN108440491A (zh) 2018-08-24

Family

ID=63199207

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810296610.9A Pending CN108440491A (zh) 2018-03-30 2018-04-03 含有多个螺碳的螺-环丙基对二烯酮类化合物及其制备方法

Country Status (1)

Country Link
CN (1) CN108440491A (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114644578A (zh) * 2022-04-12 2022-06-21 贵州大学 一种氮杂环卡宾催化的含环丙烷骨架烯酮化合物的制备方法及用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017109061A1 (en) * 2015-12-23 2017-06-29 Ieo - Istituto Europeo Di Oncologia S.R.L. Spirocyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
CN107641080A (zh) * 2017-09-29 2018-01-30 安徽师范大学 一种含螺环结构的二氢萘酮类衍生物及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017109061A1 (en) * 2015-12-23 2017-06-29 Ieo - Istituto Europeo Di Oncologia S.R.L. Spirocyclopropylamine derivatives useful as inhibitors of histone demethylases kdm1a
CN107641080A (zh) * 2017-09-29 2018-01-30 安徽师范大学 一种含螺环结构的二氢萘酮类衍生物及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PING QIAN等: "N‑Iodosuccinimide-Initiated Spirocyclopropanation of Styrenes with1,3-Dicarbonyl Compound for the Synthesis of Spirocyclopropanes", 《JOURNAL OF ORGANIC CHEMISTRY》 *
闫丹丹: "通过对亚甲基苯醌与溴代米氏酸的串联反应构建螺环化合物的初步研究", 《中国化学会第十二届全国物理有机化学学术会议》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114644578A (zh) * 2022-04-12 2022-06-21 贵州大学 一种氮杂环卡宾催化的含环丙烷骨架烯酮化合物的制备方法及用途
CN114644578B (zh) * 2022-04-12 2023-05-30 贵州大学 一种氮杂环卡宾催化的含环丙烷骨架烯酮化合物的制备方法及用途

Similar Documents

Publication Publication Date Title
Enthaler A straightforward zinc-catalysed reduction of sulfoxides to sulfides
CN110183450B (zh) 一种2-芳基吲唑并马来酰亚胺类稠合多环化合物的合成方法
CN104098607B (zh) 含三环己基膦的单膦单氮杂环卡宾镍(ii)配合物及其应用
Mao et al. Novel Schiff base complexes as catalysts in aerobic selective oxidation of β-isophorone
CN109096162B (zh) 一种钪催化硫醇对邻亚甲基苯醌的亲核加成反应方法
CN113620918A (zh) 一种通过路易斯酸催化[3+2]环加成反应合成螺环类化合物的方法
CN108440491A (zh) 含有多个螺碳的螺-环丙基对二烯酮类化合物及其制备方法
Meshram et al. Bismuthtriflate-catalyzed Reaction of N-Alkylisatins with Allyltrimethylsilane
CN109810147B (zh) 芘标记的苯并咪唑氮杂环卡宾钯金属配合物及制备和应用
US8835628B2 (en) Stable and highly tunable metathesis catalysts
WO2016197580A1 (zh) α-烷基支链取代的α-氨基酸衍生物的合成方法
CN106032371B (zh) 一种1,3-二烯烃的制备方法
TWI642658B (zh) 茚並異喹啉衍生物的製備方法
CN105859718A (zh) 一种铜催化的含氮多杂环化合物的制备方法
CN110240572B (zh) 一种反式-1,1-环丙烷二羧酸酯的合成方法
CN109942432B (zh) 一种三芳基甲醇类化合物及其合成方法
CN108383754B (zh) 一类芳基肟脂化合物的制备方法和应用
CN106008191A (zh) 一种多取代二芳基化合物的合成方法
CN108794420B (zh) 基于四甲基螺二氢茚骨架的双噁唑啉配体化合物及其中间体和制备方法与用途
CN110256307A (zh) 一种合成亚砜类化合物的方法
CN115232163B (zh) 一种硅中心手性分子化合物及其制备方法与应用
US11897827B1 (en) Carbon isotope exchange mediated by vanadium complexes
CN113666882B (zh) 维生素e微胶束参与的异恶唑啉类化合物的水相制备方法
JP7271009B2 (ja) １，３－ジアリール置換テトラゾロン内塩の合成方法
CN108440549A (zh) 螺环吲哚类化合物的合成方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180824

RJ01 Rejection of invention patent application after publication